PharmaCorp Announces a Significant C$20 Million Offering
PharmaCorp Rx Inc. (“PharmaCorp” or the “Company”) (TSXV: PCRX) has recently revealed an exciting development in its strategy to strengthen its market presence. The company announced an upsized public offering aimed at raising C$20 million, driven by a notable demand from investors.
Details of the Offering
On November 6, 2025, PharmaCorp entered into a revised agreement with a leading syndicate of underwriters, spearheaded by Canaccord Genuity Corp. and Acumen Capital Finance Partners Limited. Together, they have committed to acquiring 47.7 million units at a price of C$0.42 per unit, amounting to substantial gross proceeds for the company.
Each unit consists of a common share coupled with half of one common share purchase warrant. Investors will enjoy the benefit of these warrants, as they will allow them to acquire additional shares at an exercise price of C$0.50 within a 24-month period, post-Closing Date.
Utilization of Proceeds
The financial inflow from this offering will primarily fuel future acquisition opportunities and support general working capital needs, essential for sustaining growth and operational efficiency.
Closing Remarks and Regulatory Approvals
The anticipated closing date for this offering is expected to occur around November 12, 2025, and is contingent upon the completion of formal documentation and the receipt of regulatory approvals, including endorsement from the TSX Venture Exchange.
Underwriter's Over-Allotment Option
PharmaCorp has granted the underwriters an over-allotment option, allowing them to purchase additional units or warrants within a 30-day window. This mechanism fortifies market stability and caters to potential over-allotments.
Investment Highlights
The offering will be formalized through a prospectus supplement to the existing base shelf prospectus, ensuring transparency and compliance with Canadian securities regulations. This is a vital avenue for allowing investors to engage with PharmaCorp's strategic operations comprehensively.
About PharmaCorp
PharmaCorp stands at the forefront of pharmacy acquisition and ownership in Canada, concentrating on empowering pharmacists as equity partners and facilitating smooth transitions for retiring pharmacy owners. The company is dedicated to expanding its network of community pharmacies under the PharmaChoice Canada banner. Currently, PharmaCorp operates seven pharmacies and aims to broaden its presence by acquiring more locations, thereby reinforcing its strategic alliance with PharmaChoice Canada.
Engaging with Pharmacy Owners
PharmaCorp is eager to connect with pharmacy owners contemplating succession or sales in a seamless manner. Their acquisition program is designed to prioritize a smooth transition that preserves legacy while continuing to deliver exceptional service to communities.
Contact Information
For inquiries, potential partners or investors can reach out to:
Mr. Alan Simpson
Suite #203, 303 Wellman Lane
Saskatoon, SK S7T 0J1
Tel: (306) 536-3771
Frequently Asked Questions
What is the purpose of PharmaCorp's recent offering?
The offering aims to raise C$20 million to support future acquisitions and enhance general working capital.
Who are the underwriters for this deal?
The underwriters leading this offering are Canaccord Genuity Corp. and Acumen Capital Finance Partners Limited.
What does each unit in the offering consist of?
Each unit consists of one common share and half of a common share purchase warrant.
When is PharmaCorp expected to close this offering?
The offering is expected to close around November 12, 2025, pending regulatory approvals.
How can pharmacy owners engage with PharmaCorp?
PharmaCorp welcomes discussions with pharmacy owners looking to transition their businesses and can be contacted for more information.
